Controlled sumoylation of the mevalonate pathway enzyme HMGS-1 regulates metabolism during aging

Significance The mevalonate pathway plays a critical role in cholesterol homeostasis and cancer development, two major challenges in modern medicine. Consequently, cholesterol-reducing medications (statins) that target this pathway are the best-selling pharmaceutical drugs in history. Beyond regulat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Proceedings of the National Academy of Sciences - PNAS 2014-09, Vol.111 (37), p.E3880-E3889
Hauptverfasser: Sapir, Amir, Tsur, Assaf, Koorman, Thijs, Ching, Kaitlin, Mishra, Prashant, Bardenheier, Annabelle, Podolsky, Lisa, Bening-Abu-Shach, Ulrike, Boxem, Mike, Chou, Tsui-Fen, Broday, Limor, Sternberg, Paul W
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Significance The mevalonate pathway plays a critical role in cholesterol homeostasis and cancer development, two major challenges in modern medicine. Consequently, cholesterol-reducing medications (statins) that target this pathway are the best-selling pharmaceutical drugs in history. Beyond regulation of the enzyme HMG-CoA reductase, little is known about additional posttranslational regulatory nodes in the mevalonate pathway or how this cascade is controlled with age. We have discovered a regulatory circuit that controls HMGS-1, the first enzyme of the mevalonate pathway, during aging. HMGS-1 is regulated by posttranslational ubiquitination and age-dependent sumoylation. Sumoylation is reversed by the spatiotemporally controlled activity of a specific small ubiquitin-like modifier protease. This conserved molecular circuit could serve as a handle for targeting the mevalonate pathway in future therapeutics.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.1414748111